IMAB news

Latest 1 stories · newest Nov 9, 2026

IMAB

ImageneBio reports Q3 financial results and updates olevaprubart trial timelines

ImageneBio reported $126.6 million in cash as of Q3 2026, which funds operations into Q1 2028. The company announced top line data for its AD trial in Q4 2027 and initiated a phase 2 study in alopecia areata.

Earnings Nov 9, 2026 sentiment +0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same IMAB feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/IMAB/newsSTART FREE